Greg Shaw

Has grant

Honorary Associate Professor

University College London
Country flagUnited Kingdom
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Improving outcomes for men undergoing surgery for prostate cancer. A study to evaluate the feasibility of a multicentre randomised controlled trial of frozen section technology to improve oncological and functional outcomes at robotic radical prostatectomy.

Open Date: 2018-04-01

Close Date: 2021-03-31

Grant: Close

Early androgen responsive genes in man and the role of fatty acid synthase as a therapeutic target in prostate cancer.

Open Date: 2011-08-01

Close Date:

Articles (1)

Purpose: The purpose was to investigate combined PARP and androgen inhibition in primary prostate cancer and understand the biological mechanisms underlying clinical efficacy, especially in the absence of mutations in homologous recombination (HR) repair pathways. Patients and Methods: The primary objective was to measure PARP inhibition, and the secondary objectives were to assess safety and feasibility. Participants received olaparib for 2 weeks before prostatectomy and were randomly assigned or not assigned (1:1) to degarelix. We analyzed diagnostic biopsy and radical prostatectomy samples for PARylated protein expression using IHC. Exploratory analyses included tumor gene sequencing, mutation analysis, and RNA sequencing (RNA-seq) using both bulk and single-cell RNA-seq performed on pretreatment and posttreatment tissues. Results: PARylated protein expression was significantly reduced in both cohorts, with no drug-related delays in radical prostatectomy. The gene set enrichment analysis identified distinct treatment response signatures related to olaparib in both cohorts and showed downregulation of androgen response genes after olaparib + degarelix treatment. Transcript profiling revealed an upregulation of the p53 hallmark, which was more pronounced with the combination treatment. Canonical cell-cycle progression hallmarks, including E2F targets and the G 2 –M checkpoint, were suppressed across all cases, correlating with a HR-deficient transcriptional signature. Single-nuclear RNA-seq indicated a greater increase in inflammatory response pathway activity within tumor epithelia after combination treatment. Conclusions: Transcriptomic analysis identified common hallmark alterations reflecting the combined impact of PARP inhibitor and androgen blockade on cell-cycle progression. We observed a shared phenotypic response to combination therapy across prostate cancers without known HR repair gene alterations. This suggests alternative mechanisms rather than antiandrogen-induced HR deficiency.

Year:

2025

Collaborators (5)

Vincent J. Gnanapragasam

Professor of Urology

University of Cambridge

UNITED KINGDOM
View details

Tamsin Robb

Research Associate

University of Cambridge

UNITED KINGDOM
View details

Mark Linch

Associate Professor of Oncology

-

UNITED KINGDOM
View details

Simon Pacey

-

UNITED KINGDOM
View details

ANNE WARREN

Associate Lecturer

University of Cambridge

UNITED KINGDOM
View details